Gesynta Pharma开始在全欧洲190名妇女中进行Vipoglanstat(一种非激素内分子硬化药物)的第二阶段试验。 Gesynta Pharma started a Phase 2 trial testing vipoglanstat, a non-hormonal endometriosis drug, in 190 women across Europe.

Gesynta Pharma已开始其第2阶段的NOVA试验,在一项评估Vipoglanstat(一种用于内分泌硬化的非激素、非类阿片药物)的研究中为第一位病人施药。 Gesynta Pharma has begun its Phase 2 NOVA trial, dosing the first patient in a study evaluating vipoglanstat, a non-hormonal, non-opioid drug for endometriosis. 这一试验将让整个欧洲约190名妇女在四个月经周期内测试两剂毒品与安慰剂,重点是在非月经日减轻疼痛,同时采取包括期痛、性疼痛、类阿片使用和生活质量在内的二级措施。 The trial will enroll about 190 women across Europe to test two doses of the drug versus placebo over four menstrual cycles, focusing on pain relief on non-menstrual days, with secondary measures including period pain, sexual pain, opioid use, and quality of life. MRI将评估子宫内膜病灶的变化。 MRI will assess changes in endometriotic lesions. Vipoglanstat针对的是mPGES-1,一种与造成疼痛的孕育物相关的酶,在以前的研究中显示出安全和前景。 Vipoglanstat targets mPGES-1, an enzyme linked to pain-causing prostaglandins, and has shown safety and promise in earlier studies. 预计将在2027年取得最佳成果。 Top-line results are expected in 2027.